Results 31 to 40 of about 12,335 (206)
B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. [PDF]
PLoS ONE, 2013 B7-H3 is a member of the B7-family of co-stimulatory molecules, which has been shown to be broadly expressed in various tumor tissues, and which plays an important role in adaptive immune responses.
Ling Wang +8 more
doaj +1 more source
B7-H3 immunoregulatory roles in cancer
Biomedicine & Pharmacotherapy, 2023 B7 homolog 3 (B7-H3, also called CD276) is a checkpoint of B7 family that is aberrantly and consistently expressed in several human cancers, and its overexpression correlates with weak prognosis. B7-H3 is expressed on a number of cells, and it acts as a driver of immune evasion.
openaire +2 more sources
Assessment of plasma B7-H3 levels in pediatric patients with different degrees of surgical stress [PDF]
, 2016 Background: Surgical stress initiates a series of host hormone, metabolism and immune responses, which predominantly affect the homeostatic mechanism of patients with major surgery.
Feng, Xing +8 more
core +1 more source
Blood, 2015 In this issue of Blood , results from [Veenstra et al][1] highlight an important role of the B7-superfamily member B7-H3 (CD276) in allogeneic bone marrow transplantation.[1][2] ![Figure][3] (A) (Top) Transfer of allogeneic T cells into B7-H3–deficient animals leads to an increased ...
openaire +2 more sources
B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry, 2020 Background: Targeted Radioimmunotherapy (RIT) is an attractive approach to selectively localize therapeutic radionuclides to malignant cells within primary and metastatic tumors while sparing normal tissues from the effects of radiation. Many human malignancies express B7-H3 on the tumor cell surface, while expression on the majority of normal tissues
Benjamin B, Kasten +3 more
openaire +3 more sources
B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma
Cancers, 2023 B7-H3 is a 4Ig transmembrane protein that emerged as a tumor-associated antigen in neuroblastoma. It belongs to the B7 family, shows an immunoregulatory role toward NK and T cells, and, therefore, has been included in the growing family of immune checkpoints.
Bottino, Cristina +3 more
openaire +2 more sources
The anti-B7-H3 blocking antibody MJ18 does not recognize B7-H3 in murine tumor models
, 2023 AbstractThe immune checkpoint molecule B7-H3 is regarded as one of the most promising therapeutic targets for the treatment of human cancers. B7-H3 is highly expressed in many cancers and its expression has been associated to impaired antitumor immunity and poor patient prognosis.
Nammor, Talah +3 more
openaire +2 more sources
B7-H3 in Brain Malignancies: Immunology and Immunotherapy
International Journal of Biological Sciences, 2023 The immune checkpoint B7-H3 (CD276), a member of the B7 family with immunoregulatory properties, has been identified recently as a novel target for immunotherapy for refractory blood cancers and solid malignant tumors. While research on B7-H3 in brain malignancies is limited, there is growing interest in exploring its therapeutic potential in this ...
Guo, Xiaopeng +4 more
openaire +2 more sources
Scientific Reports, 2021 B7-H3 (also known as CD276) is associated with aggressive characteristics in various cancers. Meanwhile, in alveolar rhabdomyosarcoma (ARMS), PAX3-FOXO1 fusion protein is associated with increased aggressiveness and poor prognosis.
Takuyo Kanayama +7 more
doaj +1 more source
Frontiers in Immunology, 2021 B7 homolog 3 (B7-H3) is a recently found superfamily B7 molecule and therefore has significant involvement in immunological regulation. However, the relationships of B7-H3 expression with the tumor microenvironment (TME), response to immunotherapy, and ...
Wanzun Lin +24 more
doaj +1 more source